StreetInsider.com News Articles

Natera to present 21 studies on transplant test at ATC

Thu, 18 Jun 2026 06:01:24 -0400

Natera, Inc. (NASDAQ: NTRA) announced it will present 21 studies, including seven oral presentations, at the American Transplant Congress (ATC), scheduled for June 20-24, 2026. The presentations focus on the company's Prospera donor-derived cell-free DNA (dd-cfDNA) test for kidney, heart, lung, and multi-organ transplant monitoring.

Two studies are among the highlighted data. The PEDAL study, involving 346 kidney transplant patients with non-rejection biopsy results, found that 18.2% had positive Prospera results. Those patients showed significantly higher rates of adverse outcomes, including more than six times the rate of graft loss compared to patients with negative results.

A separate analysis from the ProActive

Natera to present 21 studies on transplant test at ATC

Thu, 18 Jun 2026 06:01:24 -0400

A separate analysis from the ProActive

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

Thu, 18 Jun 2026 06:00:00 -0400

Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transplant.

Some of the most anticipated Prospera study data to be

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

Thu, 18 Jun 2026 06:00:00 -0400

Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs

Some of the most anticipated Prospera study data to be

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

Thu, 18 Jun 2026 06:00:00 -0400

Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs

Some of the most anticipated Prospera study data to be

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

Thu, 18 Jun 2026 06:00:00 -0400

Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs

Some of the most anticipated Prospera study data to be

Form 4 Natera, Inc. For: Jun 15 Filed by: Sheena Jonathan

Wed, 17 Jun 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26661606.html

Form 4 Natera, Inc. For: Jun 15 Filed by: Sheena Jonathan

Wed, 17 Jun 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26661606.html

Form 4 Natera, Inc. For: Jun 16 Filed by: Chapman Rowan E

Wed, 17 Jun 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26661607.html

Form 4 Natera, Inc. For: Jun 16 Filed by: Chapman Rowan E

Wed, 17 Jun 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26661607.html

Form 4 Natera, Inc. For: Jun 12 Filed by: Rabinowitz Matthew

Tue, 16 Jun 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260616/26655810.html

Form 4 Natera, Inc. For: Jun 12 Filed by: Rabinowitz Matthew

Tue, 16 Jun 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260616/26655810.html

Natera board expands to 12 with appointment of Thomas Lynch

Tue, 16 Jun 2026 16:11:58 -0400

Natera, Inc. (NASDAQ: NTRA) announced that its Board of Directors has increased its size from eleven to twelve members and appointed Thomas Lynch as a director, effective June 2, 2026.

Lynch will serve as a Class I director, with an initial term expiring at the 2028 annual meeting of stockholders. The board determined that Lynch qualifies as an independent director under the Securities Act of 1933 and the listing standards of the Nasdaq Stock Market.

Lynch has been appointed to the Human Capital Committee of the board. According to the company's statement, no arrangement or understanding exists between Lynch and any other

Natera board expands to 12 with appointment of Thomas Lynch

Tue, 16 Jun 2026 16:11:58 -0400

Natera, Inc. (NASDAQ: NTRA) announced that its Board of Directors has increased its size from eleven to twelve members and appointed Thomas Lynch as a director, effective June 2, 2026.

Lynch has been appointed to the Human Capital Committee of the board. According to the company's statement, no arrangement or understanding exists between Lynch and any other

Form 8-K Natera, Inc. For: Jun 11

Tue, 16 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26654118.html

Form 8-K Natera, Inc. For: Jun 11

Tue, 16 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26654118.html

Form 8-K/A Natera, Inc. For: Jun 02

Tue, 16 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26654154.html

Form 8-K/A Natera, Inc. For: Jun 02

Tue, 16 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26654154.html

Form 144 Natera, Inc. Filed by: Chapman Rowan E

Tue, 16 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260616/26653952.html

Form 144 Natera, Inc. Filed by: Chapman Rowan E

Tue, 16 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260616/26653952.html

Form 144 Natera, Inc. Filed by: Rabinowitz Matthew

Fri, 12 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260612/26641589.html

Form 144 Natera, Inc. Filed by: Rabinowitz Matthew

Fri, 12 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260612/26641589.html

RBC Capital Starts Natera (NTRA) at Outperform

Thu, 11 Jun 2026 16:07:03 -0400

RBC Capital analyst Dan Leonard initiates coverage on Natera (NASDAQ: NTRA) with a Outperform rating and a price target of $275.00.

The analyst comments " We are resuming coverage of Natera (NTRA) with an Outperform rating and $275 price target. Our constructive view reflects Natera's growth opportunities in minimal residual disease (MRD) monitoring, a $15B+ total addressable market (TAM) where Natera has a dominant share. We believe Natera's market position is durable and see a continued catalyst path for improved reimbursement and clinical adoption of MRD testing."

For an analyst ratings summary and ratings history on Natera click here. For more

RBC Capital Starts Natera (NTRA) at Outperform

Thu, 11 Jun 2026 16:07:03 -0400

RBC Capital analyst Dan Leonard initiates coverage on Natera (NASDAQ: NTRA) with a Outperform rating and a price target of $275.00.

For an analyst ratings summary and ratings history on Natera click here. For more

Form 4 Natera, Inc. For: Jun 05 Filed by: Marcus Gail Boxer

Tue, 09 Jun 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260609/26625326.html